Founder & Chief Executive Officer
I built MD Trials around a simple belief:
Canada has the talent, institutions and scientific capability to be a much stronger force in global clinical research. What we need is the infrastructure and execution to match that potential.
My perspective comes from more than a decade of working across clinical research from multiple sides of the table. I began coordinating Phase I oncology studies at the Cross Cancer Institute and the Alberta Health Services Phase I unit, later worked as a Clinical Research Associate at TRIO monitoring trials, managed medical device and health technology studies, and ultimately moved into building organizations responsible for clinical development and site execution.
I hold a Master’s degree in Biology from the University of Calgary and a Master’s degree in Biotechnology from the University of Mumbai.
Today, I lead MD Trials across two complementary businesses: MD Trials CRO, our specialty clinical research organization, and MDTrials Sites, our growing network of Canadian clinical research sites.
Together, they were built to solve a problem I have seen repeatedly throughout my career: promising research can only move forward when strong science is matched by strong execution.
OF EXPERTISE
What I Have Learned
Successful clinical research is rarely the result of one remarkable idea or one exceptional investigator.
It happens when good science is connected with capable investigators, the right patients, disciplined operations and teams willing to keep solving problems when a study becomes difficult.
That is the kind of organization I want MDTrials to be: rigorous in how we work, practical in how we solve problems and accountable for the commitments we make.
Why This Work Matters
Clinical trials matter far beyond our industry.
Almost every medicine we rely on today exists because patients, investigators, scientists, coordinators, sponsors and regulators were willing to participate in the long and demanding process of turning an idea into evidence.
Being part of developing treatments that our families and communities may one day depend on is extraordinarily meaningful work. Clinical research may be a specialized field, but its impact belongs to all of us.
That responsibility is something I never want us to lose sight of as MDTrials grows.
Canada’s Opportunity
I believe Canada is entering an important period for clinical research.
Our population is growing and becoming increasingly diverse. Healthcare systems are under significant economic pressure, while the global life sciences industry is becoming more selective about where it invests and places clinical trials.
Those pressures also create an opportunity.
Canada has exceptional physicians, sophisticated healthcare institutions, diverse patient populations, strong scientific talent and a regulatory environment capable of supporting high-quality research.
What we have not built at sufficient scale is the infrastructure needed to translate those advantages into consistent, predictable trial execution.
That is the gap MDTrials was created to help close.
Technology will be an important part of that future. Advances in artificial intelligence are already changing how trials are designed, how sites and patients are identified, how data are reviewed and how potential risks are detected earlier.
My view on technology is straightforward: we should automate the work, but never the accountability.
Technology should reduce administrative burden and help good people make better decisions. It should not replace professional judgement. Every output that touches a regulated record must ultimately be reviewed and approved by a qualified person. That principle will remain fundamental to how we operate.
Values I care
Straight Answers
One of the values I care most about is giving people straight answers, even when those answers are difficult.
Having worked on intensive early-phase studies, I do not see enrolment simply as a number on a dashboard. And having monitored trials and carried responsibility for studies that needed answers, I do not see timelines as administrative targets.
There are patients, investigators, teams and significant investments behind every one of those numbers.
If I believe a study is unlikely to succeed at a particular site or within a particular patient population, I would rather have that conversation during feasibility than allow everyone to discover the problem six months into enrolment.
When we partner with investigators, I want them to understand both sides of clinical research: what it can bring to their patients and their practice, and what doing it well will genuinely demand from them.
Trust is built by being realistic at the beginning and accountable throughout the study.
CLINICAL TRIALS
UNDERSTANDING THE CULTURE
The Long Road
Building a clinical research company has reinforced something I learned much earlier in my career: very few worthwhile things move in a straight line.
Studies encounter obstacles. Recruitment slows. Timelines change. Strategies need to be reconsidered. Companies experience setbacks.
The answer is not to pretend those problems do not exist. It is to understand them, take responsibility for them and keep working until there is a credible path forward.
That persistence is the culture I want to build at MDTrials.
We are ambitious about what clinical research in Canada can become, realistic about what it takes to get there, and relentless about doing the work required to move promising medicines and technologies toward the patients who need them.
CONTACT ME
That is why I built MDTrials — and why I remain deeply committed to the work ahead.